Status:
Recruiting
Phase:
Phase II
Official Title:
Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
NCT ID:
NCT#03698019
Link to Full Details:
Description:
Arm 1 (Adjuvant): Surgery followed by Pembrolizumab every 3 weeks for 18 doses
Arm 2 (Neoadjuvnat): Pembrolizumab every 3 weeks for 3 doses followed by surgery then followed with any additional 15 doses of pembrolizumab every 3 weeks
Eligibility:
Male and Female – 18 years and older
Inclusion Criteria:
- Resectable melanoma, Stage III or IV (N1b, N1c, N2b, N2c, N3b, or N3c)
- May have received prior immunotherapy adjuvant therapy
Exclusion Criteria:
- Uveal melanoma
- No previous neoadjuvant treatment for melanoma